WAM
NVCR icon

WFA Asset Management’s NovoCure NVCR Stock Holding History

WFA Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-70
Closed -$1.05K – 252
2023
Q4 		$1.05K Hold
70
– – ﹤0.01% 213
2023
Q3 		$1.13K Hold
70
– – ﹤0.01% 233
2023
Q2 		$2.9K Hold
70
– – ﹤0.01% 211
2023
Q1 		$4.21K Hold
70
– – ﹤0.01% 205
2022
Q4 		$5.13K Hold
70
– – ﹤0.01% 178
2022
Q3 		$5.32K Hold
70
– – ﹤0.01% 192
2022
Q2 		$4.87K Buy
+70
New +$5.27K ﹤0.01% 177

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WFA Asset Management's NVCR Position: Q1 2024 in Review

WFA Asset Management sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 70 shares — an estimated $1.05K sold.

WFA Asset Management first reported a position in NVCR in Q2 2022 and held it in 7 quarters. The position peaked at $5.32K in Q3 2022. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

  • WFA Asset Management reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
  • WFA Asset Management sold 70 NovoCure shares in Q1 2024, an estimated $1.05K.
  • WFA Asset Management first reported a position in NovoCure in Q2 2022 and held it in 7 quarters.
  • WFA Asset Management's NovoCure position peaked at $5.32K in Q3 2022.
  • 237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on WFA Asset Management's 13F filing for Q1 2024, filed 19 Apr 2024.